|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2001-4-3
|
|
pubmed:abstractText |
The oral administration of 5-fluorouracil (5-FU) is hindered by erratic bioavailability due to catabolism of 5-FU by the enzyme dihydropyrimidine dehydrogenase (DPD) in the gastrointestinal tract. Eniluracil is a potent inactivator of DPD which results in 100% oral bioavailability of 5-FU. Leucovorin (LV) is another biochemical modulator of 5-FU that potentiates inhibition of thymidylate synthase, the primary target of 5-FU. The goal of this study was to determine the antitumor activity and toxicity of an oral regimen containing eniluracil, 5-FU, and LV in patients with colorectal carcinoma.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/5-ethynyluracil,
http://linkedlifedata.com/resource/pubmed/chemical/Antimetabolites, Antineoplastic,
http://linkedlifedata.com/resource/pubmed/chemical/Dihydrouracil Dehydrogenase (NAD ),
http://linkedlifedata.com/resource/pubmed/chemical/Enzyme Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Fluorouracil,
http://linkedlifedata.com/resource/pubmed/chemical/Leucovorin,
http://linkedlifedata.com/resource/pubmed/chemical/Oxidoreductases,
http://linkedlifedata.com/resource/pubmed/chemical/Oxidoreductases Acting on CH-CH...,
http://linkedlifedata.com/resource/pubmed/chemical/Thymidylate Synthase,
http://linkedlifedata.com/resource/pubmed/chemical/Uracil
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright 2001 American Cancer Society.
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
91
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1256-63
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:11283924-Administration, Oral,
pubmed-meshheading:11283924-Adult,
pubmed-meshheading:11283924-Aged,
pubmed-meshheading:11283924-Aged, 80 and over,
pubmed-meshheading:11283924-Antimetabolites, Antineoplastic,
pubmed-meshheading:11283924-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:11283924-Carcinoma,
pubmed-meshheading:11283924-Colorectal Neoplasms,
pubmed-meshheading:11283924-Dihydrouracil Dehydrogenase (NAD+),
pubmed-meshheading:11283924-Disease Progression,
pubmed-meshheading:11283924-Enzyme Inhibitors,
pubmed-meshheading:11283924-Female,
pubmed-meshheading:11283924-Fluorouracil,
pubmed-meshheading:11283924-Humans,
pubmed-meshheading:11283924-Leucovorin,
pubmed-meshheading:11283924-Male,
pubmed-meshheading:11283924-Middle Aged,
pubmed-meshheading:11283924-Oxidoreductases,
pubmed-meshheading:11283924-Oxidoreductases Acting on CH-CH Group Donors,
pubmed-meshheading:11283924-Thymidylate Synthase,
pubmed-meshheading:11283924-Uracil
|
|
pubmed:year |
2001
|
|
pubmed:articleTitle |
Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal carcinoma.
|
|
pubmed:affiliation |
Divisions of Medical Science and Population Science, Fox Chase Cancer Center, Philadelphia, Pennslyvania, USA. nj_meropol@fccc.edu
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Multicenter Study,
Clinical Trial, Phase II
|
